0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Dermatology |

This Month in Archives of Dermatology FREE

[+] Author Affiliations

Section Editor: Robin L. Travers, MD


Arch Dermatol. 2011;147(2):157. doi:10.1001/archdermatol.2011.7.
Text Size: A A A
Published online

IMPACT OF MELANOMA ON PATIENTS' LIVES AMONG 562 SURVIVORS

Although the prognosis is relatively good for about 80% of patients with melanoma, they remain at risk for disease progression and have an increased risk of developing subsequent melanomas. In this cross-sectional survey, Holterhues et al used the 36-Item Short-Form Health Survey, Impact of Cancer (IOC) questionnaire, and specific melanoma-related questions to demonstrate that women were significantly more likely to report higher levels of both positive and negative IOC. The impact of melanoma appeared to be specific and more substantial in women, which suggests that women may need additional care to cope optimally with their melanoma.

See dst05029

A RANDOMIZED COMPARISON OF METHODS OF SELECTING NARROWBAND UV-B STARTING DOSE TO TREAT CHRONIC PSORIASIS

When topical therapies for psoriasis prove insufficient, narrowband (NB) UV-B is often the standard next-line therapy. The minimal erythemal dose (MED) frequently guides the NB UV-B starting dose, but it remains unclear if this method offers greater efficacy than skin phototype–based starting doses. In this randomized, double-blind, clinical trial, Dawe et al demonstrate that there were no significant differences in the number of treatments to clearance among patients randomly allocated to a fixed starting dose based on skin phototypes compared with 70% MED or 50% MED.

See dst05032

A UNIQUE PRESENTATION OF AN EPSTEIN-BARR VIRUS–ASSOCIATED NATURAL KILLER/T-CELL LYMPHOPROLIFERATIVE DISORDER IN A WHITE MALE ADOLESCENT

Extranasal natural killer (NK)/T-cell lymphoma (ENKTL) and aggressive NK-cell leukemia are strongly associated with Epstein-Barr virus (EBV) and most often occur in middle-aged individuals. In this case report, Summers et al describe a 15-year-old boy who developed painful subcutaneous nodules and plaques on his abdomen, thighs, and legs while undergoing treatment with infliximab. Atypical EBV+ lymphoid cells of NK-cell origin were found to be infiltrating the subcutaneous adipose tissue and were also noted in the bone marrow, liver, stomach, and colon. This is the first case of an EBV+ ENKTL developing in the setting of tumor necrosis factor inhibitor therapy.

See dob05021

TWO CASES OF MULTIPLE SPITZ NEVI

Spitz nevi are benign melanocytic proliferations with distinct histologic features. They are typically solitary, but some patients develop multiple lesions. Although most Spitz nevi are karyotypically normal, some may have balanced gains with tetraploidy, and others may have an isolated gain in locus 11p. In this report, Boone et al describe 2 patients with multiple Spitz nevi. Fluorescence in situ hybridization revealed balanced tetraploidy in one case and normal diploid cells in the other. Neither case showed diagnostic changes of melanoma, demonstrating how molecular techniques may be used to confirm the diagnosis of Spitz nevus in challenging cases.

See dob05036

DEVELOPMENT OF THE CLASI AS A TOOL TO MEASURE DISEASE SEVERITY AND RESPONSIVENESS TO THERAPY IN CUTANEOUS LUPUS ERYTHEMATOSUS

The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a clinical tool that quantifies disease activity and damage in cutaneous lupus erythematosus (LE). The activity score is based on the degree of erythema, scale, mucosal lesions, and nonscarring alopecia. In this cohort study of 75 patients with cutaneous or systemic LE, Klein et al demonstrate that this tool can be used to categorize patients into severity groups and identify clinically significant improvements in disease activity. This analysis provides a foundation for the practical use of the CLASI in clinical trials.

See dst05038

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

267 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs